Overview

Effect of AQW051 in Patients With Memory Impairment

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals